DAGLA (Diacylglycerol Lipase Alpha), also known as DAGLα, is the primary biosynthetic enzyme for 2-arachidonoylglycerol (2-AG), the most abundant endocannabinoid in the mammalian brain[1][2]. As a membrane-bound enzyme located primarily in the endoplasmic reticulum, DAGLA catalyzes the hydrolysis of diacylglycerol (DAG) to produce 2-AG, which then acts as a retrograde neurotransmitter at cannabinoid CB1 receptors throughout the central nervous system[3]. The enzyme plays critical roles in synaptic plasticity, neuroprotection, inflammation regulation, and has emerged as a significant target in understanding and treating Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[4][5].
DAGLA is a large type I transmembrane protein consisting of 1048 amino acids with a molecular weight of approximately 120 kDa[1:1]. The protein exhibits several distinct structural domains that facilitate its enzymatic function and subcellular localization.
N-terminal Signal Peptide:spans residues 1-40, targets the protein for secretion and membrane insertion
Multiple Transmembrane Domains (1-6):spans residues 100-450 and anchors the protein to the endoplasmic reticulum membrane. These hydrophobic helices traverse the membrane multiple times, creating a characteristic serpentine topology[6]
Catalytic Lipase Domain:spans residues 500-800 and contains the active site for diacylglycerol hydrolysis. The catalytic triad (Ser-Asp-His) follows the canonical lipase motif[7]
GXSXG Consensus Sequence: Located at residues 472-476, defines the active serine nucleophile
C-terminal Regulatory Domain:spans residues 850-1048, modulates enzyme activity and subcellular localization
X-ray crystallography and cryo-EM studies have revealed[6:1][7:1]:
DAGLA operates within a coordinated biosynthetic cascade[1:2][3:1]:
2-AG functions as a retrograde neurotransmitter with unique properties[3:2][8]:
| Regulatory Mechanism | Effect on DAGLA | Physiological Consequence |
|---|---|---|
| Calcium influx | Activation | Activity-dependent 2-AG production |
| Protein kinase A | Phosphorylation/inhibition | Modulates synaptic plasticity |
| Protein kinase C | Phosphorylation/activation | Gq-coupled receptor signaling |
| Gq protein coupling | Activation | Receptor-stimulated production |
| pH changes | pH-dependent activity | Synaptic microenvironment effects |
DAGLA and the 2-AG pathway have complex, multifaceted roles in Alzheimer's disease[4:1][9]:
Neuroprotective Effects
Synaptic Function
Therapeutic Implications
In Parkinson's disease, DAGLA signaling is significantly altered[5:1][10]:
Dopaminergic Signaling Modulation
Neuroinflammation
L-DOPA-Induced Dyskinesia
The endocannabinoid system, including DAGLA, shows therapeutic relevance in multiple sclerosis[12]:
DAGLA provides neuroprotection in stroke models[13]:
The anti-inflammatory properties of 2-AG are mediated through[14]:
| Compound | Target | Effect | Stage |
|---|---|---|---|
| DO34 | DAGLA activator | Neuroprotection | Preclinical |
| JZL184 | MAGL inhibitor | Increases 2-AG | Clinical trials |
| THL | DAGLA inhibitor | Research tool |
Small molecule activators of DAGLA are being developed for[18][19]:
Inhibitors have research and therapeutic applications:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| CB1 Receptor | Endocannabinoid signaling | Retrograde neurotransmission |
| CB2 Receptor | Immune modulation | Anti-inflammatory effects |
| PLCβ | Lipid signaling | DAG production |
| MAGL | Endocannabinoid metabolism | 2-AG termination |
| FAAH | Endocannabinoid metabolism | 2-AG/2-AGE termination |
| GRP55 | Potential receptor | Non-CB1/CB2 target |
DAGLA sits at the intersection of multiple lipid signaling pathways[1:3]:
Bisogno et al. [Cloning of the first sn1-DAG lipases (2003)](https://doi.org/10.1016/S0092-8674(03). Cell. 2003. ↩︎ ↩︎ ↩︎ ↩︎
Zhang et al. DAGLA structure and function (2018). Neuropharmacology. 2018. ↩︎
Kano et al. Endocannabinoid signaling in the brain (2009). Physiological Reviews. 2009. ↩︎ ↩︎ ↩︎
Mulder et al. Endocannabinoid signaling in AD (2019). Journal of Alzheimer's Disease. 2019. ↩︎ ↩︎
Zhang et al. Endocannabinoid system in PD (2017). Movement Disorders. 2017. ↩︎ ↩︎
Himmelreich et al. Crystal structure of human DAGLA (2021). Nature. 2021. ↩︎ ↩︎
Chen et al. Catalytic mechanism of DAGL enzymes (2019). Journal of Biological Chemistry. 2019. ↩︎ ↩︎
Alger & Kim, Retrograde endocannabinoid signaling (2011). Trends in Neurosciences. 2011. ↩︎
Bedse et al. Therapeutic potential of 2-AG in AD (2017). Neurobiology of Aging. 2017. ↩︎
Pagano et al. DAGLA in PD models (2020). Brain. 2020. ↩︎
Martinez et al. Endocannabinoids and L-DOPA dyskinesia (2019). Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019. ↩︎
Loría et al. Endocannabinoid system in MS (2018). Lancet Neurology. 2018. ↩︎
Zhang et al. 2-AG in cerebral ischemia (2019). Journal of Cerebral Blood Flow & Metabolism. 2019. ↩︎
Chiurchiu et al. Endocannabinoids and neuroinflammation (2018). Nature Reviews Neurology. 2018. ↩︎
Agrawal et al. DAGLA genetic variants (2018). Translational Psychiatry. 2018. ↩︎
Gao et al. DAGLA knockout mouse phenotype (2010). Cell. 2010. ↩︎
Tchantchou et al. DAGLA in neurodegeneration models (2021). Neuropharmacology. 2021. ↩︎
Baggelaar et al. DAGLA as therapeutic target (2017). Trends in Pharmacological Sciences. 2017. ↩︎
Hwang et al. DAGLA modulators for CNS disorders (2020). Journal of Medicinal Chemistry. 2020. ↩︎ ↩︎